Citations

Clear

13603 citation(s) found for "_, _".

Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study
Meng, Ruogu , Liu, Duanke, Guo, Yuchen, Wang, Yunhe, Gao, Yaqing , Huang, Zhe , Zhu, Liang , Zeng, Chao , Ma, Jun , Irani, Anushka, Lei, Guanghua, Irani, Anushka , Chen, Li , Xie, Junqing , Irani, Anushka , Kelleher, Eoin , Guo, Yuchen, Wang, Yunhe, Yuan, Shuai , Dong, Yanhui, Lei, Guanghua, Prieto‐Alhambra, Daniel

Mayo Clinic

Advanced Science | September 30, 2025 | Volume: 12 | Issue: 47 | Pages: No page available

10.1002/advs.202507691 | PMID 41025730 Get It

Abstract Chronic widespread pain (CWP) remains challenging due to its heterogeneous causes and complex mechanisms. A total of 2920 plasma proteins are analyzed from 29,254 UK Biobank participants. A total of 256 proteins are identified as cross‐sectionally correlated with CWP. A simple (top 10 proteins) and comprehensive (all significant proteins) proteomic‐based score (ProtS) is created for CWP diagnosis, both outperforming and improving the existing clinical score (area under the curve, AUC: 0.801, 0.723, and 0.791 alone, and 0.856 and 0.880 in combination). In addition, the protein score predicted 13‐years risk of pain‐related traits over the body, including pain onset, progression, and intensity; Moreover, it has stronger associations with nociplastic pain and fibromyalgia compared to nociceptive and neuropathic pain, implying a unique protein signature of different pain mechanisms. Finally, among 434 candidate proteins prioritized in the observational analysis, 18 are corroborated with causal relevance by Mendelian randomization, and importantly, four (CA14, DPEP1, LGALS3, and TNF) showed potential as novel drug targets repurposed for treating CWP.
Acute Valve Syndrome Before Aortic Valve Replacement: Impact on Clinical Outcomes, Health Care Costs, and Resource Use
Généreux, Philippe , Lindman, Brian R. , Pîbarot, Philippe , Baron, Suzanne J. , Asselin, Chantal , Dratch, Alissa , Murphy, Shannon , Chikermane, Soumya , Thourani, Vinod H. , Koulogiannis, Konstantinos , Schwartz, Allan , Leon, Martin B. , Gillam, Linda D. , Lindman, Brian R , Pibarot, Phillippe , Baron, Suzanne J , Asselin, Chantal , Dratch, Alissa , Murphy, Shannon M E , Chikermane, Soumya , Koulogiannis, Kostantinos P , Schwartz, Allan , Leon, Martin B. , Pellikka, Patricia A , Gillam, Linda D , Généreux, Philippe , Giustino, Gennaro , Pellikka, Patricia A.

Mayo Clinic

Journal of the American Heart Association | September 30, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.043486 | PMID 41025452 Get It

Background A classification system describing clinical presentation before aortic valve replacement (AVR) has recently been proposed (stable valve syndrome [SVS]), mildly symptomatic (progressive valve syndrome), or with acute and severe signs and symptoms (acute valve syndrome [AVS]). We aimed to evaluate the clinical impact, health care costs, and resource use associated with the mode of clinical presentation at the time of AVR among patients presenting with aortic stenosis. Methods Using the Market Clarity database (2017–2023), patients >18 years old with aortic stenosis and undergoing AVR (transcatheter or surgical) were included. Patients were categorized as SVS, progressive valve syndrome, or AVS based on their clinical presentation during the 1 year before AVR. All‐cause death, heart failure hospitalization, total health care costs (index hospitalization plus 1‐year follow‐up), and resource use were compared across clinical presentation groups using adjusted regression models. Results Of the 24 075 patients undergoing AVR for aortic stenosis, 270 (1.1%) had SVS, 10 195 (42.3%) progressive valve syndrome, and 13 610 (56.5%) AVS. Compared with SVS, AVS presentation was associated with increased risk of 1‐year death (adjusted hazard ratio [aHR], 2.93 [95% CI, 1.1–7.8]; P =0.03) and heart failure hospitalization (aHR, 4.15 [95% CI, 1.6–11.1]; P <0.01) after AVR. The total costs of AVR and 1‐year follow‐up were significantly higher in both the progressive valve syndrome (difference $27 410 [$13 507–$41 314]) and AVS groups (difference $36 267 [$22 302–$50 232]) compared with patients with SVS. Conclusions AVS was frequent among patients undergoing AVR and was associated with increase in death, heart failure hospitalization, health care costs, and resource use 1 year after AVR, and SVS presentation was associated with the best clinical and economic outcomes.
Blood Pressure, Safety and Clinical Efficacy of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Trial
Mentz, Robert J. , McMullan, Ciaran J. , Wojdyla, Daniel , Anstrom, Kevin J. , Barash, Irina , Bonaca, Marc P. , Borentain, Maria, Corda, Stefano , Gates, Davis, Lam, Carolyn, Lewis, Eldrin F. , O'Connor, Christopher M., Reddy, Yogesh N.V. , Rosano, Giuseppe M.C., Saldarriaga, Clara , Senni, Michele, Teixeira, Pedro Pinto , Udelson, James E. , Urbinati, Alessia , Vlajnic, Vanja , Xing, Aiwen, Zannad, Faiez, Group, for the VICTOR Study, Nishimura, Rick , Mentz, Robert J , Butler, Javed , Ezekowitz, Justin A. , Lam, Carolyn S.P. , Lindenfeld, JoAnn , O’Connor, Christopher M. , Ponikowski, Piotr , Senni, Michele , Voors, Adriaan A. , Zannad, Faı̈ez , Group, for the VICTOR Study

Mayo Clinic

European Journal of Heart Failure | September 29, 2025 | Volume: 27 | Issue: 12 | Pages: 2825-2836

10.1002/ejhf.70033 | PMID 41020754 Get It

Abstract Aims The efficacy and safety of vericiguat in patients with chronic heart failure with reduced ejection fraction (HFrEF) on contemporary heart failure (HF) therapies and without recent worsening was investigated in the VICTOR trial, yet some subgroups may be more susceptible to symptomatic hypotension. Methods and results Among VICTOR trial participants that received at least one dose of study drug or placebo, we describe the systolic blood pressure (SBP) trajectories over time (mean change from baseline), symptomatic hypotension events and efficacy of vericiguat in potentially vulnerable patient subgroups: lower baseline blood pressure (SBP ≤110 mmHg), older patients (&gt;75 years) and those taking angiotensin receptor–neprilysin inhibitors (ARNI) or sodium–glucose co-transporter 2 inhibitors (SGLT2i) at baseline. The efficacy outcomes of cardiovascular death and HF hospitalization and cardiovascular death alone across baseline SBP were examined using Cox proportional hazards models. Overall SBP trajectories showed a small initial decline from baseline in vericiguat-treated patients compared with placebo (placebo-corrected differences of −1.17 [−1.84, −0.50], p = 0.0007) that was relatively stable throughout follow-up. This trajectory was similar in those &gt;75 years (vs. younger) as well as those receiving ARNI or SGLT2i (as compared with those not receiving these) or those with SBP ≤110 mmHg at baseline (compared with &gt;110 mmHg). Symptomatic hypotension occurred in 11.3% of vericiguat-treated patients compared with 9.2% of placebo-treated patients with an adjusted hazard ratio of 1.24 (95% confidence interval 1.06–1.46), which was similar across age, SBP, SGLT2i and ARNI groups (all interaction p &gt;0.05). The treatment effect of vericiguat compared with placebo on the efficacy outcomes was similar across the spectrum of baseline SBP (both interaction p &gt;0.15). Conclusions Vericiguat showed a slight adjusted decrease in SBP and resulted in more symptomatic hypotension compared with placebo but was overall well-tolerated in a broad population with HFrEF on contemporary therapy even among those predisposed to hypotension. Treatment effects on efficacy outcomes were consistent regardless of baseline SBP.
Response to: An International ASXL3 Natural History Study: Deep Phenotypic Analyses Including Detailed Reports of a Milder Phenotype, Novel Associations,
Hasan, Shemonti , Melville, David M. , Chaaban, Mohammad Karam, Harahsheh, Ehab , Olarewaju, Bukola A., Baudhuin, Linnea M. , Shamoun, Fadi , Osundiji, Mayowa A. , Melville, David, Chaaban, Mohammad K, Osundiji, Mayowa Azeez , Shen, Wei

Mayo Clinic

American Journal of Medical Genetics Part A | September 29, 2025 | Volume: 200 | Issue: 2 | Pages: 559-561

10.1002/ajmg.a.64272 | PMID 41017488 Get It

From the Editor-in-Chief’s Desk: Advancing Patient-Centered Care in ADHD, Anxiety, and Mood Disorders
Croarkin, Paul E.

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | September 29, 2025 | Volume: 35 | Issue: 10 | Pages: 537-538

10.1177/10445463251384639 | PMID 41017326 Get It

Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study
Lu, Wen , Ziman, Alyssa , Vassallo, Ralph R. , Poisson, Jessica , Grandoni, Jessica, Jacquot, Cyril , Germain, Marc , Young, Pampee P. , Collaborative, The Biomedical Excellence for Safer Transfusion, Ziman, Alyssa , Vassallo, Ralph R , Jacquot, Cyril , Dunbar, Nancy M , Cohn, Claudia S , Young, Pampee , Lu, Wen , Singh, Umesh Pratap , Shih, Andrew W. , Raval, Jay S. , Dunbar, Nancy M. , Cohn, Claudia S. , Collaborative, The Biomedical Excellence for Safer Transfusion

Mayo Clinic

Transfusion | September 29, 2025 | Volume: 65 | Issue: 11 | Pages: 2091-2104

10.1111/trf.18434 | PMID 41017017 Get It

Abstract Background Cryoprecipitated antihemophiliac factor (cryo) is primarily used to replenish fibrinogen in acquired coagulopathy. Little has been reported about its usage patterns within hospitals with respect to patient population, frequency of use, and dosing. Study design and methods Cryo production and usage data were collected over 5 years from July 1, 2016, to June 30, 2021, from nationally based blood collection centers in the United States (U.S. n = 2) and Canada ( n = 2) and from eight large academic hospitals, respectively. Usage data for a similar product, purified fibrinogen concentrate were also collected from four hospitals. Results Two U.S. blood collectors reported increases in cryo production normalized to total whole blood collections from 17.4% in 2016 to 22.3% in 2021 and from 16.4% in 2016 to 20.2% in 2021. In contrast, in Canada cryo manufacturing increased slightly in one region (11.3%–12.9%) and decreased (8.0%–2.0%) in the other. Cryo utilization, defined as numbers of patients treated normalized to the inpatient census, and dose administered per patient did not consistently increase and differed significantly between hospitals participating in the study ( p < .0001). Likewise, the departments that most frequently transfused cryo varied between hospitals. Similarly, variations in practice were observed for fibrinogen concentrate usage. Conclusion While much of Canada and Europe have moved towards using fibrinogen concentrate, two large U.S. collectors have increased cryo distribution. The lack of standardization and variability in the clinical practice regarding the use of cryo and fibrinogen concentrate reported by study sites may be attributable to practitioner preference, availability, and/or cost rather than adherence to published evidence or guidelines.
Diminished preparatory physiological responses in people with dementia: associations with caregiver health and relationship quality
Chen, Kuan‐Hua , Scheffer, Julian A. , Chen, Enna , Yee, Claire , Wells, Jenna L. , Lwi, Sandy J. , Grimm, Kevin J. , Merrilees, Jennifer , Yee, Claire , Grimm, Kevin , Levenson, Robert W , Levenson, Robert W.

Mayo Clinic

The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences | September 27, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/geronb/gbaf187 | PMID 41021459 Get It

Abstract Objectives Emotional impairments in people with dementia can be taxing for family caregivers. However, caregivers differ in their resilience to these challenges. We previously found that, compared to healthy controls and people with Alzheimer’s disease, people with frontotemporal lobar degeneration (FTLD) have smaller physiological responses when anticipating upcoming emotional stimuli. This impairment may leave these people with FTLD unprepared for upcoming emotional stimuli because they cannot mount responses needed for appropriate behaviors, which may create stress and difficulties for caregivers. We examined (a) whether smaller preparatory physiological responses in people with dementia are associated with lower emotional well-being and physical functioning in caregivers; and (b) whether these associations are moderated by the dyads’ relationship quality. Methods A total of 158 individuals with FTLD or Alzheimer’s disease and their family caregivers participated. Preparatory physiological responses in people with dementia were quantified as decreases in cardiac interbeat intervals from baseline to an instruction period, during which they were told they would be watching an upcoming emotional film. Caregivers self-reported their emotional well-being, physical functioning, and relationship quality with the people with dementia. Results Smaller preparatory physiological responses in people with dementia were associated with lower emotional well-being (but not physical functioning) in caregivers. This association was moderated by relationship quality (i.e., weakened for caregivers in higher-quality relationships). Discussion Findings advance understanding of risk and resilience factors for negative caregiver outcomes. Positive interpersonal processes in high-quality relationships (e.g., positive appraisal of aberrant behaviors) may buffer caregivers from the impact of emotional impairments in people with dementia.
Poster 116: Outcomes of Isolated Medial Patellofemoral Ligament Reconstruction after First-Time and Recurrent Patellar Instability - Recurrence, Return to Sport, and Osteochondral Injury: Data from the JUPITER Cohort
Propp, Bennett E. , Smith, Haley D. , Wimberly, Audrey , Nguyen, Joseph , Group, Jupiter Study, Brady, Jacqueline Munch , Marigi, Erick M. , Dennis, Elizabeth , Pahapill, Natalie , Group, Jupiter Study, Stein, Beth E. Shubin , Parikh, Shital N.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00213 Get It

Objectives: Current standard of care after a First-Time patellar instability event is non-operative management, with exceptions for patients with osteochondral fracture or loose body requiring immediate surgical intervention, patients with significant pathoanatomy, or contralateral patellar instability. For recurrent patellar instability, there is controversy as to when isolated medial patellofemoral ligament reconstruction (MPFL-R) is enough. The purpose of this study is to determine (1) the comparative outcomes of isolated MPFL-R after first-time patellar instability (FTPI) and recurrent patellar instability (RPI) and (2) the impact of osteochondral injury on outcomes after surgical treatment of FTPI. Methods: A prospective, multicenter cohort study (JUPITER: Justifying Patellar Instability Treatment by Results) database was queried for patients who underwent patellar stabilization surgery (PSS) between December 2016 and September 2022. Patients were included if they underwent a medial patellofemoral ligament reconstruction (MPFL-R) for FTPI or RPI. Those with less than 2 years of clinical follow-up, revision PSS, or concomitant bony procedures at the time of MPFL-R were excluded. Independent t-tests were performed to compare means for continuous variables, and chi-squared tests were performed to compare frequency for categorical variables, between groups. Results: A total of 739 patients met inclusion criteria with a mean age of 15.6 ± 3.3 years, and 59.9% female sex. FTPI occurred in 216 (27.2%) patients, and of these 104 (48.1%) sustained an operative chondral or osteochondral lesion. Those with FTPI had a significantly greater trochlear depth (2.9 mm vs. 2.6 mm; P = .048), but a significantly lower rate of pathological trochlear bump > 5 mm (52.3% vs. 67.8%; P = .008) than those with RPI (Table 1). Among the FTPI cohort, those with treatment of a chondral lesion were less likely to have patella alta (Caton-Deschamps Index > 1.3) (14.9% vs. 41.3%, P = .006), and less frequently had a mild or severe J-sign (25.0% vs. 42.7%, p = .016) than those without a chondral intervention (Table 2). Postoperatively, there were no differences with rates of recurrent instability (8.3% vs. 12.3%; P = .130) or return to sport (90.4% vs. 94.5%; P = .182) between FTPI and RPI, respectively (Table 3). There were no differences with rates of recurrent instability (7.6% vs. 9.1%; P = .807) or return to sport (89.1% vs. 91.7%; P = .755) between those with or without a chondral intervention, respectively (Table 4). Conclusions: This study demonstrates no difference in rates of recurrent post-operative instability between FTPI and RPI with rates consistent with the current literature. MPFL reconstruction remains as a durable surgical treatment option for patients presenting with either FTPI or RPI with relatively low rates of recurrent instability. In this patient population, patella alta was found to be protective of osteochondral injury which is also consistent with existing literature. Continued, long-term investigation is needed to understand outcomes for First-Time patellar instability and to better define the indications for surgical interventions in this population.
Poster 46: Trends and Outcomes of Medial Ulnar Collateral Ligament Repair with Internal Brace, Isolated Reconstruction, and ’Hybrid’ Reconstruction with Internal Brace in Professional Baseball Players: A Matched Cohort Analysis
Griffith, Timothy B. , Chalmers, Peter N., Hebert, Elizabeth, Griffith, Timothy Bryan , Pan, Xuankang , Erickson, Brandon J. , Chalmers, Peter N. , Hebert, Elizabeth, Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00157 Get It

Objectives: There is a paucity of research comparing the outcomes of medial ulnar collateral ligament (MUCL) repair with internal bracing to isolated MUCL reconstruction in professional baseball players. Further, the practice of supplementing a MUCL reconstruction with an internal brace, a "hybrid" reconstruction, has increased in the surgical treatment of MUCL injuries for professional baseball players, without any currently known published research defining the clinical outcomes of this modification. We sought to investigate the trends and outcomes of MUCL repair with internal bracing and "hybrid" MUCL reconstruction with internal bracing. Using a matched cohort analysis, we also sought to compare the clinical outcomes of both MUCL repair with internal bracing and "hybrid" MUCL reconstruction with internal bracing to isolated MUCL reconstructions, without internal bracing, in professional baseball players. Methods: The MLB Health and Injury Tracking System was used to identify all professional baseball players who underwent MUCL surgery, regardless of surgery technique, from 2010 to 2023. Professional players of all levels (MLB and MiLB) and players of all positions were included. Player demographics, injury characteristics, surgical details, and postoperative outcomes were obtained. Player demographics included age at surgery, position of play, professional level of play and surgical technique. Outcomes assessed were return to play (RTP) status, time to RTP, return to same level of play (RTSL), time to RTSL, revision MUCL surgery, and time to revision MUCL surgery, with a minimum of 2 years of follow up. Players were considered to have RTP if they participated in at least one game at any professional level. RTSL was defined as returning to the same league of professional play or higher. Patients undergoing MUCL repair and "hybrid" MUCL reconstruction with internal bracing were independently compared to propensity matched patients undergoing isolated MUCL reconstruction, without internal bracing, to assess for a difference in postoperative outcomes. Four subgroup analyses were conducted by further categorizing patients to MLB players, MiLB players, pitchers, and position players. Results: 76 patients underwent MUCL repair with internal bracing from 2016-2021 and were successfully propensity matched to 76 patients undergoing isolated MUCL reconstructions. Baseline patient demographic variables of MUCL repairs were statistically similar to those of controls except for age at time of surgery (24.5 vs 21.8; p<0.001). 81 patients underwent "hybrid" MUCL reconstructions with internal bracing from 2016-2021 and were successfully propensity matched to 81 patients undergoing isolated MUCL reconstructions. Baseline demographic variables of "hybrid" MUCL reconstructions were statistically similar to those of controls except for age at time of surgery (24.3 vs. 23.3; p=0.006). Compared to isolated MUCL reconstruction controls, all patients undergoing MUCL repair demonstrated significantly shorter time to RTP (mean 421.2 vs. 546.2 days; p<0.001), shorter time to RTSL (mean 436.2 vs. 558.8 days; p<0.001), and shorter time to revision (mean 465.2 vs.1648 days; p=0.036). The number of patients who RTP at any level, RTSL, and number of revision surgeries were not significantly different. Compared to isolated MUCL reconstruction controls, all patients undergoing "hybrid" MUCL reconstructions demonstrated no significant differences with respect to the number of patients who RTP, time to RTP, number of patients who RTSL, days to RTSL, number of revision surgeries, and time to revision surgery. In MLB players only, compared to isolated MUCL reconstruction controls, patients who underwent MUCL repairs demonstrated significantly shorter time to RTP (mean 282.8 vs 507.3 days; p=0.008) and shorter time to RTSL (mean 299.7 vs. 598.0 days; p = 0.024). No other outcomes were significant. In MLB players only, compared to isolated MUCL reconstruction controls, patients who underwent "hybrid" MUCL reconstructions demonstrated significantly shorter time to RTP (mean 436.2 vs. 525.3 days; p=0.026). No other outcomes were significant. In MiLB players only, compared to isolated MUCL reconstruction controls, patients who underwent MUCL repairs demonstrated significantly shorter time to RTP (mean 444.3 vs 550.7 days; p<0.001) and shorter time to RTSL (mean 451.7 vs. 556.5 days; p<0.001). No other outcomes were significant. In MiLB players only, compared to isolated MUCL reconstruction controls, patients who underwent "hybrid" MUCL reconstructions demonstrated no significant differences in outcomes. In evaluating pitchers only, compared to isolated MUCL reconstruction controls, patients undergoing MUCL repair demonstrated significantly shorter time to RTP (mean 421.7 vs. 578.6 days; p<0.001), shorter time to RTSL (mean 434.8 vs. 591.6 days; p <0.001), and shorter time to revision surgery (mean 465.2 vs.1648 days; p=0.036). No other outcomes were significant. In pitchers only, compared to isolated MUCL reconstruction controls, patients undergoing "hybrid" MUCL reconstructions demonstrated significantly shorter time to RTP (mean 488.1 vs. 549.0 days; p=0.013) and shorter time to RTSL (mean 505.7 days vs. 577.0 days, respectively; p=0.021). No other outcomes were significant. Notably, all revision surgeries in occurred in pitchers only. Conclusions: Based on a matched cohort anaylsis of professional baseball players undergoing MUCL surgery, when compared to an isolated MUCL reconstruction, MUCL repair with internal bracing may allow for a shorter time to RTP and RTSL, with a shorter time to revision surgery. For pitchers, "hybrid" MUCL reconstruction may allow for a shorter time to RTP and RTSL. For MLB players, "hybrid" MUCL reconstruction may allow for a shorter RTP.
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Fu, Sunyang , Kwak, Min Ji , Ahn, Jaerong, Yue, Zhiyi , Ranganath, Shreyas, Applegate, Joseph R., Wang, Liwei , Li, Chenyu , Toth, Kelly M, Girard, Timothy D., Osborne, John D. , Kennedy, Richard , Garduno-Rapp, Nelly-Estefanie, Reeder, Phillip , Murphy, Thomas J. , Heling, Jia, Sohn, Sunghwan , Visweswaran, Shyam, Wang, Yanshan , Girard, Timothy D. , Li, Chenyu , Rousseau, Justin F , Yan, Chao , Murphy, Tyler J , Park, Chan Mi , Bernstam, Elmer V , Visweswaran, Shyam , Liu, Hongfang , Girard, Timothy D , Fu, Sunyang , Kennedy, Richard E , Osborne, John D , Wang, Yanshan , Ahn, Jaerong, Applegate, Joseph R, Wen, Andrew , Morris, Michele M. , Toth, Kelly M, Rousseau, Justin F. , Chen, You , Patel, Mayur Bipin , Malin, Bradley , Jia, Heling, Pagali, Sandeep R. , Palmer, Allyson K. , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | September 26, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/gerona/glaf207 | PMID 41017643 Get It

Abstract Background Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.